A Ludwig Lausanne study discovered that pre-existing networks of killer T cells and activated myeloid cells in tumors predict whether patients with advanced melanoma are likely to respond to adoptive cell therapy using tumor infiltrating lymphocytes (TIL-ACT). Successful therapy expanded and activated these networks.
Read MoreThe Ludwig Institute just launched a three-year team science initiative focused on immunometabolism, which explores the metabolic crosstalk between tissues and the immune cells that patrol them. Read all about the project and the collaborations it has established across Ludwig Branches, Centers and their host institutions.
Three early-career Ludwig scientists—two graduate students and a postdoc all set to set up his own lab—tell us a little about their lives, science and avocational interests.
Read More
